We are live on ! Find out more
WVE icon

Wave Life Sciences

183 hedge funds and large institutions have $1.59B invested in Wave Life Sciences in 2024 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 76 increasing their positions, 38 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 38

92% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 24

73% more call options, than puts

Call options by funds: $9.23M | Put options by funds: $5.33M

61% more capital invested

Capital invested by funds: $986M → $1.59B (+$605M)

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

13% more funds holding

Funds holding: 162183 (+21)

9.58% less ownership

Funds ownership: 93.91%84.33% (-9.6%)

Holders
183
Holders Change
+21
Holders Change %
+12.96%
% of All Funds
2.41%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.05%
New
46
Increased
76
Reduced
38
Closed
24
Calls
$9.23M
Puts
$5.33M
Net Calls
+$3.9M
Net Calls Change
+$3.54M
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$225M
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$119M -$1.08M -81,247 -0.8%
BlackRock
3
BlackRock
New York
$116M +$27.5M +2,061,740 +28%
MC
4
Maverick Capital
Texas
$102M -$23.8M -1,786,278 -18%
DCM
5
Driehaus Capital Management
Illinois
$83M +$11.4M +853,589 +15%
MCM
6
M28 Capital Management
Connecticut
$70.1M -$6.67M -500,000 -8%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$63.1M +$26.3M +1,972,262 +63%
KCM
8
Kynam Capital Management
New Jersey
$60.6M
BG
9
Bellevue Group
Switzerland
$50.6M
6CM
10
683 Capital Management
New York
$46.8M -$5.54M -415,000 -10%
SL
11
Siren LLC
Connecticut
$46.4M -$26.3M -1,970,681 -34%
Vanguard Group
12
Vanguard Group
Pennsylvania
$39.4M +$3.94M +294,956 +10%
EA
13
Emerald Advisers
Pennsylvania
$39.1M +$3.75M +280,859 +10%
Primecap Management
14
Primecap Management
California
$31.2M -$817K -61,180 -2%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$30.6M +$2.68M +201,087 +9%
State Street
16
State Street
Massachusetts
$30M +$1.41M +105,349 +5%
EMFAT
17
Emerald Mutual Fund Advisers Trust
Pennsylvania
$23.9M -$2.57M -192,432 -9%
Artisan Partners
18
Artisan Partners
Wisconsin
$23.6M -$717K -53,680 -3%
P
19
Pfizer
New York
$23.2M +$25M +1,875,000 New
Fidelity Investments
20
Fidelity Investments
Massachusetts
$22.6M +$3.84M +287,530 +19%
Loomis, Sayles & Company
21
Loomis, Sayles & Company
Massachusetts
$20.5M +$22.2M +1,660,866 New
AAA
22
Affinity Asset Advisors
New York
$18.6M +$1.33M +100,000 +7%
MB
23
MPM BioImpact
Massachusetts
$18.4M +$11.5M +864,766 +138%
Millennium Management
24
Millennium Management
New York
$14.6M +$4.39M +329,173 +39%
Morgan Stanley
25
Morgan Stanley
New York
$13.1M +$5.53M +414,051 +64%

WVE Hedge Fund Activity: Q4 2024 in Review

183 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Wave Life Sciences (WVE) for Q4 2024, worth a combined $1.59B — up 61% from $986M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new WVE positions and 24 closed out — a net gain of 22 holders — while 76 added to existing stakes and 38 trimmed.

The largest buyer was BlackRock, adding an estimated $27.5M. The largest seller was Siren LLC, cutting an estimated $26.3M.

  • 183 institutional investors held Wave Life Sciences (WVE) as of Q4 2024, up from 162 in Q3 2024.
  • Funds reported $1.59B of Wave Life Sciences stock for Q4 2024, up 61% quarter-over-quarter.
  • 46 funds opened new Wave Life Sciences positions in Q4 2024 and 24 closed out, a net change of +22 holders.
  • The largest Wave Life Sciences buyer in Q4 2024 was BlackRock, an estimated $27.5M added.
  • The largest Wave Life Sciences seller in Q4 2024 was Siren LLC, an estimated $26.3M sold.

Based on aggregated 13F filings for Q4 2024.